Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists

Author： Szabóó Nikoletta   Kincses Zsigmond Tamáás   Véécsei Láászlóó  

Publisher： Informa Healthcare

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.7, Iss.4, 2011-04, pp. : 441-455

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adenosine A 2A receptor antagonists as new agents for the treatment of Parkinson's disease

By Richardson P.J.   Kase H.   Jenner P.G.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 9, 1997-10 ,pp. : 338-344

Elsevier

Access to resources Recommend Favorite

Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.  

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists and Parkinson's Disease: State of the Art and Future Directions

By  

Current Pharmaceutical Design, Vol. 14, Iss. 15, 2008-05 ,pp. : 1475-1489

Bentham Science Publishers

Access to resources Recommend Favorite

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

By Perez-Lloret Santiago   Merello Marcelo  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1097-1107

Informa Healthcare

Access to resources Recommend Favorite